ClinicalTrials.gg
RecruitingNCT06717698Updated Mar 11, 2026

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

A Phase 2 interventional study of NNC0519-0130 and Placebo in Chronic Kidney Disease, sponsored by Novo Nordisk A/S. Recruiting at 147 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
465
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S — 5 open to participants now, 6 under way, 1 of them phase 3. Renal Insufficiency, Chronic · Novo Nordisk A/S.

Planned enrollment
5th of 18
465 · median 128
Started
2024
with 4 others
Phase 2
5 of 29
1 open now
Registered
21st of 29
by date

Among the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S, this one is the 5th largest by planned enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2024, is one of 5 in phase 2, and was the 21st registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

5 of the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S, or all of them as a file.
02

Study summary

The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity. The participants will either get NNC0519-0130 (a new medicine), semaglutide (a medicine that doctors can already prescribe), or placebo (a "dummy" substance). Which treatment the participant will get is decided by chance. The study will last for up to 43 weeks.

03

Conditions studied

  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female of non-, or male.

    • For US only: Female of childbearing potential using highly effective non-systemic methods of with low user-dependency at least 2 months prior to screening and willingness to continue using it through-out the study, or male.
  • Age 18 years or above at the time of signing the .
  • Diagnosed with type 2 diabetes mellitus greater than or equal to (≥) 180 days before screening, or not diagnosed with type 2 diabetes mellitus.

    • of 6.5 percentage (%)-10.5 percentage (%) [48 - 91 millimoles per mole (mmol/mol)] (both inclusive) if diagnosed with type 2 diabetes mellitus, or HbA1c of less than (\<)6.5 percentage (%) [\<48 mmol/mol] if not diagnosed with type 2 diabetes mellitus.
  • greater than or equal to (≥) 27.0 kilogram per square metre (kg/m\^2) at screening.
  • Kidney impairment defined by serum creatinine and cystatin C-based Egfr greater than or equal to (≥) 15 and less than (\<) 90 mL/min/1.73 m\^2.
  • Albuminuria defined by Urine Albumin-to-Creatinine Ratio (UACR) greater than or equal (≥)100 and less than (\<) 5000 milligram per gram (mg/g).
  • Treatment with maximum labelled or tolerated dose of an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment is or not tolerated, in the opinion of the investigator. Treatment dose must be stable for at least 30 days prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using highly effective non-systemic with low user-dependency.
  • Lupus nephritis or antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
  • Receiving therapy for primary or secondary renal disease within 6 months prior to screening.
  • Use of any glucagon-like peptide-1 (GLP-1) RA (including medication with GLP-1 RA activity, e.g., GIP/GLP-1 RA) within 90 days prior to screening.
  • Myocardial infarction, stroke, , or hospitalization for unstable angina pectoris within 180 days before screening.
  • Chronic or intermittent haemodialysis or peritoneal dialysis within 90 days before screening.
  • Only applicable for participants with type 2 diabetes (T2D): Uncontrolled and potentially unstable diabetic retinopathy or diabetic maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Presence or history of malignant neoplasms or in situ carcinomas (other than basal or squamous cell skin cancer, low-risk prostate cancer, or in-situ carcinomas of the cervix or carcinoma in situ/high grade prostatic intraepithelial neoplasia (PIN)) within 5 years before screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
465 participants (estimated)

Study arms

  • Experimental
    Dosing scheme a: NNC0519-0130

    Participants will receive once-weekly subcutaneous (s.c) injections of NNC0519-0130 following a fixed dose escalation until the maintenance dose is reached.

    Drug: NNC0519-0130

  • Placebo comparator
    Dosing scheme a: Placebo

    Participants will receive NNC0519-0130 matched placebo s.c. once-weekly.

    Drug: Placebo

  • Experimental
    Dosing scheme b: NNC0519-0130

    Participants will receive once-weekly s.c injections of NNC0519-0130 following a fixed dose escalation until the maintenance dose is reached.

    Drug: NNC0519-0130

  • Placebo comparator
    Dosing scheme b: Placebo

    Participants will receive NNC0519-0130 matched placebo s.c. once-weekly.

    Drug: Placebo

  • Experimental
    Dosing scheme c: NNC0519-0130

    Participants will receive once-weekly s.c injections of NNC0519-0130 following a fixed dose escalation until the maintenance dose is reached.

    Drug: NNC0519-0130

  • Placebo comparator
    Dosing scheme c: Placebo

    Participants will receive NNC0519-0130 matched placebo s.c. once-weekly.

    Drug: Placebo

  • Experimental
    Dosing scheme d: NNC0519-0130

    Participants will receive once-weekly s.c injections of NNC0519-0130 following a fixed dose escalation until the maintenance dose is reached.

    Drug: NNC0519-0130

  • Placebo comparator
    Dosing scheme d: Placebo

    Participants will receive NNC0519-0130 matched placebo s.c. once-weekly.

    Drug: Placebo

  • Active comparator
    Dosing scheme e: Semaglutide

    Participants will receive once-weekly s.c injections of semaglutide with a dose escalation done until maintenance dose is reached.

    Drug: Semaglutide

Interventions

  • NNC0519-0130 will be administered subcutaneously.

  • DrugPlacebo

    Placebo matching NNC0519-0130 will be administered subcutaneously.

  • Semaglutide will be administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Change in urinary albumin-to-creatinine ratio (UACR) at week 12

    Measured as a ratio to baseline.

    Time frame: From baseline (week 0) to end of a given maintenance dose period (week 12)

  2. Change in urinary albumin-to-creatinine ratio (UACR) at week 24

    Measured as a ratio to baseline.

    Time frame: From baseline (week 0) to end of a given maintenance dose period (week 24)

  3. Change in urinary albumin-to-creatinine ratio (UACR) at week 36

    Measured as a ratio to baseline.

    Time frame: From baseline (week 0) to end of a given maintenance dose period (week 36)

Secondary outcomes

  1. Change in estimated glomerular filtration rate (eGFR) (creatinine and cystatin C-based Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] 2021)

    Measured in mililitre per minute per 1.73 square metre (mL/min/1.73 m\^2).

    Time frame: From baseline (week 0) to end of treatment (week 36)

  2. Change in estimated glomerular filtration rate (eGFR) (creatinine-based CKD-EPI 2021)

    Measured in mililitre per minute per 1.73 square metre (mL/min/1.73 m\^2).

    Time frame: From baseline (week 0) to end of treatment (week 36)

  3. Relative change in body weight

    Measured in percentage (%).

    Time frame: From baseline (week 0) to end of treatment (week 36)

  4. Achievement of greater than or equal to (≥) 5 percentage (%) weight reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 36)

  5. Achievement of greater than or equal to (≥) 10 percentage (%) weight reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 36)

  6. Change in waist circumference

    Measured in centimetres (cm).

    Time frame: From baseline (week 0) to end of treatment (week 36)

  7. Change in glycated haemoglobin (HbA1c)

    Measured in percentage point (%-point).

    Time frame: From baseline (week 0) to end of a given maintenance dose period (week 12, 24 or 36)

  8. Change in systolic blood pressure

    Measured in millimetres of mercury (mmHg).

    Time frame: From baseline (week 0) to end of treatment (week 36)

  9. Change in diastolic blood pressure

    Measured in millimetres of mercury (mmHg).

    Time frame: From baseline (week 0) to end of treatment (week 36)

  10. Number of treatment emergent adverse events (TEAEs)

    Measured as count of events.

    Time frame: From baseline (week 0) to end of study (week 40)

07

Study locations

16 of 147 sites recruiting
  • N America Res Inst - San Dimas
    San Dimas, California 91773, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • NorCal Endocrinology and Internal Medicine
    San Ramon, California 94583, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Rocky Mount Reg VA Med-DN
    Aurora, Colorado 80045, United States
    Completed

    Not enrolling at this site — choose another above.

  • Northeast Research Institute
    Fleming Island, Florida 32003, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Encore Medical Research LLC
    Hollywood, Florida 33024, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Northeast Research Institute
    Saint Augustine, Florida 32080, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Clinical Research of Cent FL
    Winter Haven, Florida 33880, United States
    Completed

    Not enrolling at this site — choose another above.

  • Endeavor Health
    Skokie, Illinois 60077, United States
    Completed

    Not enrolling at this site — choose another above.

  • Velocity Clin. Res Valparaiso
    Valparaiso, Indiana 46383, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Elite Research Center
    Flint, Michigan 48532, United States
    Completed

    Not enrolling at this site — choose another above.

  • Clinical Research Consultants
    Kansas City, Missouri 64111-5964, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Albany Medical College
    Albany, New York 12203, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Carteret Medical Group
    Morehead City, North Carolina 28557, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Brookview Hills Research Associates, LLC
    Winston-Salem, North Carolina 27103, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Davita Clinical Research
    El Paso, Texas 79902, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Clinical Advancement Center
    San Antonio, Texas 78212, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Tekton Research
    San Antonio, Texas 78251, United States
    Completed

    Not enrolling at this site — choose another above.

  • Providence Medical Research Center
    Spokane, Washington 99204, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centro Médico CIMEL
    Lanús Este, Buenos Aires B1824KAJ, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Renalida
    Mar del Plata, Buenos Aires B7600, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centro de Investigaciones Metabólicas
    City of Buenos Aires, C1056ABI, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Instituto de Cardiología de Corrientes
    Corrientes, W3400AMY, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Instituto de Investigaciones Clinicas Mar Del Plata
    Mar del Plata, B7600FZN, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Castle Hill Medical Centre
    Castle Hill, New South Wales 2154, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Gosford Renal Research
    Gosford, New South Wales 2250, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Heart of Australia
    Chelmer, Queensland 4068, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Melbourne Renal Research Group
    Reservoir, Victoria 3073, Australia
    Not yet recruiting
  • Sunshine Hospital - Western Centre for Health Research and Education
    St Albans, Victoria 3021, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Quanta Diagnóstico Nuclear / Medicina Nuclear Alto da XV
    Curitiba, Paraná 80045-110, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Instituto Pró-Renal Brasil
    Curitiba, Paraná 80440-020, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centro de Diabetes Curitiba
    Curitiba, Paraná 80810-040, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Irmandade da Santa Casa de Misericórdia de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90020-090, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda.
    Porto Alegre, Rio Grande do Sul 90430-001, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital do Rim e Hipertensao Fundacao Oswaldo Ramos
    São Paulo, 04038-002, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • SRH - Zdrave EAD
    Bankya, 1320, Bulgaria
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Medical centre Zdrave 1 OOD
    Kozloduy, 3320, Bulgaria
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Nader Yabrudi - ASMPVBE Individual practice
    Smolyan, 4700, Bulgaria
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Medical Centre Acad. Iv. Penchev EOOD
    Sofia, 1431, Bulgaria
    Completed

    Not enrolling at this site — choose another above.

  • Medical Centre Acad. Iv. Penchev EOOD
    Sofia, 1431, Bulgaria
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • USHATE Akad. Ivan Penchev EAD, Second Clinic of Endocrinology
    Sofia, 1431, Bulgaria
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • UMHAT Sofiamed EAD
    Sofia, 1750, Bulgaria
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • UMHAT Sveta Anna Sofia AD, Second Clinic of Internal Diseases
    Sofia, 1750, Bulgaria
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • UMHAT Sveta Marina EAD, Clinic of Internal Diseases
    Varna, 9010, Bulgaria
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Nemocnice Český Krumlov, a.s.
    Český Krumlov, 381 01, Czechia
    Withdrawn

    Not enrolling at this site — choose another above.

  • MUDr. Petr Buček s.r.o.
    Frýdek-Místek, 738 01, Czechia
    Withdrawn

    Not enrolling at this site — choose another above.

  • CTC Hodonin s.r.o.
    Hodonín, 695 01, Czechia
    Withdrawn

    Not enrolling at this site — choose another above.

  • FNKV-Internal Clinic-Nephrology
    Prague, 100 34, Czechia
    Withdrawn

    Not enrolling at this site — choose another above.

  • DiaVize s.r.o.
    Prague, 140 00, Czechia
    Withdrawn

    Not enrolling at this site — choose another above.

  • IKEM Klinika nefrologie
    Prague, 140 21, Czechia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Fledip s.r.o.
    Prague, 160 00, Czechia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Internist Care s.r.o.
    Smiřice, 503 03, Czechia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Endolife Specialty Hospitals
    Guntur, Andhra Pradesh 522001, India
    Not yet recruiting
  • MS Ramaiah
    Bengaluru, Karnataka 560054, India
    Not yet recruiting
  • Government Medical College, Kozhikode
    Kozhikode, Kerala 673008, India
    Not yet recruiting
  • SMS Medical College & Hospital
    Jaipur, Rajasthan 302004, India
    Not yet recruiting
  • Diabetes, Thyroid and Endocrine Centre
    Jaipur, Rajasthan 302006, India
    Not yet recruiting
  • Diabetes Research Center, Hyderabad
    Hyderabad, Telangana 500082, India
    Not yet recruiting
  • Nizams Institute of Medical Science
    Hyderabad, Telangana 500082, India
    Not yet recruiting
  • ASL Avezzano Sulmona L'Aquila - Ospedale San Salvatore - UOC Diabetologia
    L’Aquila, Abbruzzo 67100, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Università degli studi G. D'Annunzio Chieti Pescara - CAST
    Chieti, Abruzzo 66100, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • A.O.U. Bologna_ Policlinico S.Orsola Malpighi
    Bologna, BO 40138, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliera Papa Giovanni XXIII
    Bergamo, 24127, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliera Spedali Civili di Brescia
    Brescia, 25121, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliera Luigi Sacco
    Milan, 20157, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliero Universitaria Pisana Ospedale Cisanello
    Pisa, 56124, Italy
    Not yet recruiting
  • Fondazione Policlinico Universitario Agostino Gemelli IRCS
    Roma, 00168, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Seino Internal Medicine Clinic_Internal medicine
    Koriyama-shi, Fukushima, Fukushima, Japan 963-8851, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology
    Aichi, 468-0009, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Naka Kinen Clinic_Internal medicine
    Ibaraki, 311-0113, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Naka Kinen Clinic_Internal medicine
    Ibaraki, 311-0113, Japan
    Recruiting
  • Fujisawa City Hospital_Kidney internal medicine
    Kanagawa, 251-8550, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Fujisawa City Hospital_Kidney internal medicine
    Kanagawa, 251-8550, Japan
    Recruiting
  • Higashijujo Sakai Diabetes Clinic_Internal Medicine
    Kita-ku, Tokyo, 114-0001, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Koshigaya Municipal Hospital_Internal medicine
    Saitama, 343-8577, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hanyu General Hospital_Internal Medicine
    Saitama, 348-8505, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Shinden Higashi Clinic_Internal medicine
    Sendai-shi, Miyagi, 983-0039, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Shinden Higashi Clinic
    Sendai-shi, Miyagi, 983-0039, Japan
    Recruiting
  • Omihachiman Community Medical Center_Nephrology
    Siga, 523-0082, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Omihachiman Community Medical Center_Nephrology
    Siga, 523-0082, Japan
    Recruiting
  • Tokyo-Eki Center-building Clinic_Internal Medicine
    Tokyo, 103-0027, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fukuwa Clinic_Internal Medicine
    Tokyo, 104-0031, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fukuwa Clinic_Internal Medicine
    Tokyo, 104-0031, Japan
    Recruiting
  • Fukuwa Clinic
    Tokyo, 104-0031, Japan
    Recruiting
  • Kato Clinic of Internal Medicine_Internal Medicine
    Tokyo, 125-0054, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kato Clinic of Internal Medicine
    Tokyo, 125-0054, Japan
    Recruiting
  • University Malaya Medical Centre
    Kuala Lumpur, Kuala Lumpur 59100, Malaysia
    Recruiting
  • University Malaya Medical Centre
    Lembah Pantai, Kuala Lumpur 59100, Malaysia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Raja Permaisuri Bainun Ipoh
    Ipoh, Perak 30450, Malaysia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Pulau Pinang
    George Town, Pulau Pinang 10990, Malaysia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Miri
    Miri, Sarawak 98000, Malaysia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Sibu
    Sibu, Sarawak 96000, Malaysia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Sungai Buloh
    Sungai Buloh, Selangor 47000, Malaysia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Universiti Sains Malaysia
    Kota Bharu, Kelantan, 16150, Malaysia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Prince Court Medical Centre
    Kuala Lumpur, 50450, Malaysia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Melaka
    Malacca, 75400, Malaysia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kardio Life - Tomasz Borkowski
    Włocławek, Kuyavian-Pomeranian Voivodeship 87-800, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Terpa Sp. z o.o. Sp. k.
    Lublin, Lubelskie Voivodeship 20-333, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kliniczny Szpital Wojewodzki nr 2 im. Sw. Jadwigi Krolowej w Rzeszowie
    Rzeszów, Podkarpackie Voivodeship 35-301, Poland
    Not yet recruiting
  • Uniwersytecki Szpital Kliniczny w Bialymstoku
    Bialystok, 15-276, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Uniwersytecki Szpital Kliniczny w Bialymstoku
    Bialystok, 15-276, Poland
    Recruiting

Showing the first 100 of 147 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Sep 2026, 20 months after the start.

Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's planned 20 months is close to that.

Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2024
First posted
Dec 5, 2024
StartActual
Dec 2, 2024
Primary completionEst.
Sep 1, 2026
CompletionEst.
Sep 17, 2026
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06717698
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 5, 2024
Start date
Dec 2, 2024
Primary completion
Sep 1, 2026 (estimated)
Completion
Sep 17, 2026 (estimated)
Last update
Mar 11, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NNC0519-0130

Start the discussion